Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
posted on
Mar 24, 2020 05:00PM
Koo,
Gordon et al. identified BRD2/4 as a binding partner of viral protein E.
Resverlogix states that Apabetalone was shown to disrupt this interaction.
Jupe